Quibim SL
Budget
€100 — €0
EP Access
0
accredited persons
Staff
4
2.6 FTE
EU Grants
€416,350
Mission & Goals
Quibim is company designing and creating pioneering tools that unlock imaging data to maximize drug programmes and improve patient outcomes. The company follows an AI-first approach to help detect pathologies and predict outcomes in oncology/immunotherapy, rheumatology and neurology using imaging modalities such as MRI, CT and PET. The goal is to transform imaging into actionable predictions. Quibim is specialized in big imaging infrastructures to advance the development of AI models and help real-world evidence (RWE) and biopharma partners extract new insights from images. Quibim develops novel quantitative imaging biomarkers to deeply analyze disease mechanisms, advancing in drug discovery and monitoring treatment progress through a whole-body approach.
EU Legislative Interests
- Medical Device Regulation (EU) 2017/745 - General Data Protection Regulation(GDPR) (EU) 2016/679 - Artificial Intelligence for Europe (COM(2018) 237 final) - Laying down harmonised rules on artificial intelligence (artificial intelligence act) and amending certain union legislative acts (COM(2021) 206 final). - European Union AI Act (Regulation (EU) 2024/1689)
Communication Activities
- Europe's Beating Cancer Plan - AI4HI - AI for health imaging - European Cancer Imaging Initiative - Euro-Bioimaging - European Cancer Images Initiative - FUTURE-AI guidelines
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
- AI for Health Imaging https://cordis.europa.eu/programme/id/H2020_DT-TDS-05-2020 - European Institute for Medical Imaging Research (EIBIR): https://www.eibir.org/initiatives/euroaim/ - Euro-Bioimaging https://www.eurobioimaging.eu/ - Avicenna Alliance. Association for Predictive Medicine https://avicenna-alliance.com/
Organisation Members
n/a
Commissioner Meetings
No recorded meetings with EU commissioners.